scholarly journals Analysis of Prognostic and Therapeutic Values of Drug Resistance-Related Genes in the Lung Cancer Microenvironment

2021 ◽  
Author(s):  
Liang Zhu ◽  
Peixin Chen ◽  
Hao Wang ◽  
Lishu Zhao ◽  
Haoyue Guo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Drug Resistance ◽  
T Cells ◽  
Significant Contribution ◽  
Tumor Development ◽  
Good Prognosis ◽  
Transcriptional Level ◽  
Lung Cancer Patients ◽  
Rna Polymerization ◽  
Cancer Tissues

Abstract Background: The interaction between cancer cells and stromal cells has a significant contribution in tumorigenesis and tumor development, and plays an anti-tumor immune effect under the regulation of drug resistance related genes, which affects the outcome of patients. CCDC73, DLGAP1, DSEL, ESR1, and SEC14L5 were identified as drug resistance-related genes in lung cancer. However, these genes have no clear value in lung cancer in terms of expression and prognosis.Results: The transcriptional expression level of DLGAP1 was remarkably increased in lung cancer tissues, while the transcriptional level of SEC14L5 was significantly decreased. The pathological stage of lung adenocarcinoma (LUAD) was tightly correlated with the expression of SEC14L5. The lung cancer patients with high transcription level of CCDC73 gene tended to have a good prognosis. The function of drug resistance-related genes is mainly related to RNA polymerization. Our results showed that infiltration of six types of immune cells (dendritic cells, macrophages, neutrophils, B cells, CD4+T cells, and CD8+ T cells) significantly correlated with the expression of these drug resistance-related genes.Conclusions: Novel screening for immunotherapy targets and prognostic biomarkers in lung cancer may draw inspiration from our results.

Identification of Therapeutic Targets and Prognostic Biomarkers of IGF2BPs in the Lung Cancer Microenvironment

2021 ◽  
Author(s):  
Xuanzheng Wang ◽  
Weina Kong ◽  
Fan Guo ◽  
Ruocheng Sha ◽  
Gang Zhao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
T Cells ◽  
Cancer Patients ◽  
Poor Prognosis ◽  
Binding Proteins ◽  
Rna Binding ◽  
Therapeutic Targets ◽  
Prognostic Biomarkers ◽  
Lung Cancer Patients ◽  
Cancer Tissues

Abstract Background: Lung cancer is one of the most common malignances with an ever-increasing incidence and high mortality. The insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) as RNA-binding proteins play an important role in messenger RNA (mRNA) regulation during tumor development. Even so, the expression and prognostic values of IGF2BPs in lung cancer have not been clarified.Main methods: To address this issue, the study investigated the roles of IGF2BPs in the prognosis of lung cancer by using public databases and quantitative real-time PCR (Q-PCR).Results: The transcriptional levels of IGF2BP1/2/3 in lung cancer tissues were significantly elevated, associating with pathological stages and poor prognosis of overall survival (OS) and progression-free survival (FP) in lung cancer patients. A high mutation rate of IGF2BPs (24%) was also observed of patients with lung cancer. The functions of differentially expressed IGF2BPs are primarily related to the spliceosome, hippo signaling pathway and transcriptional misregulation in cancer. Finally, we found significant correlations among the expression of IGF2BPs and the infiltration of six types of immune cells (B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells).Conclusions: The results indicated that high mRNA expression of IGF2BP1/2/3 was found in lung cancer tissues, significantly associating with tumor grades and poor prognosis of OS and FP. Our results may provide insights for the selection of therapeutic targets and prognostic biomarkers for lung cancer patients.

scholarly journals Computational methods for the analysis and prediction of drug resistance in EGFR-mutated non-small cell lung cancer patients

2021 ◽  
Author(s):  
Rizwan Qureshi
Keyword(s):  
Lung Cancer ◽  
Drug Resistance ◽  
Computational Methods ◽  
Review Paper ◽  
Small Cell ◽  
Cancer Drug ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Cancer Drug Resistance ◽  
Egfr Mutated

This is a review paper for the analysis and prediction of lung cancer drug resistance. We explore several computational methods, that can provide, biological insights for the analysis, visualization and prediction of lung cancer drug resistance.

scholarly journals Increased CD3+ T cells with a low FOXP3+/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients

2018 ◽  
Vol 32 (3) ◽  
pp. 367-375 ◽  
Author(s):  
Hyojin Kim ◽  
Hyun Jung Kwon ◽  
Yeon Bi Han ◽  
Soo Young Park ◽  
Eun Sun Kim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
T Cells ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Therapeutic Response ◽  
Cd8 T Cell ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Ratio ◽  
Lung Cancer Patients

scholarly journals Diagnostic value of α-enolase expression and serum α-enolase autoantibody levels in lung cancer

2018 ◽  
Vol 44 (1) ◽  
pp. 18-23 ◽  
Author(s):  
Lihong Zhang ◽  
Hongbin Wang ◽  
Xuejun Dong
Keyword(s):  
Lung Cancer ◽  
Lung Disease ◽  
Cancer Patients ◽  
Clinical Stage ◽  
Diagnostic Value ◽  
Smoking History ◽  
Lung Cancer Patients ◽  
Pathological Classification ◽  
Cancer Tissues ◽  
Antibody Levels

ABSTRACT Objective: To investigate the diagnostic value of α-enolase (ENO1) and serum ENO1 autoantibody levels in lung cancer. Methods: Immunohistochemistry staining and ELISA were performed to detect ENO1 expression in lung tissue and serum ENO1 autoantibody levels, respectively. Results: The expression of ENO1 was higher in lung cancer tissues than in benign lung disease tissues (p < 0.001). The proportion of lung cancer samples expressing ENO1 was not significantly different among the various pathological classification groups. The proportion of samples expressing ENO1 was higher in lung cancer patients in stages I/II than in those in stages III/IV (χ2 = 5.445; p = 0.018). The expression of ENO1 in lung cancer tissues was not associated with age, gender, or smoking history. Serum ENO1 antibody levels were significantly higher in the lung cancer group than in the benign lung disease and control groups (p < 0.001). The differences among the pathological classification groups were not statistically significant. Serum ENO1 antibody levels were also in lung cancer patients in stages I/II than in those in stages III/IV (p < 0.01). Serum ENO1 antibody levels were not associated with age, gender, or smoking history in lung cancer patients. The ROC curve representing the diagnosis of lung cancer based on ENO1 antibody levels had an area under the curve of 0.806. Conclusions: Our results suggest that high levels of ENO1 are associated with the clinical stage of lung cancer and that ENO1 expression and its serum autoantibody levels show diagnostic value in lung cancer.

scholarly journals Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation

2002 ◽  
Vol 168 (9) ◽  
pp. 4272-4276 ◽  
Author(s):  
Edward Y. Woo ◽  
Heidi Yeh ◽  
Christina S. Chu ◽  
Katia Schlienger ◽  
Richard G. Carroll ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Proliferation ◽  
T Cells ◽  
T Cell ◽  
Regulatory T Cells ◽  
Cancer Patients ◽  
Cutting Edge ◽  
T Cell Proliferation ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document